JNJ Volume Alert - JNJ 109.30 Johnson & Johnson $JNJ Hit a high of 109.33 Currently 11:15 Last price 109.30 +0.48 +0.44% With a day low of 108.55 and a current volume of 1,779,254.
JNJ Johnson & Johnson Recent Headline News
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 35 mins ago
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)
Midday Glance: Pharmaceuticals companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)
Midday Glance: Medical Devices companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
Reinvesting Dividends Turbo-Charges Total Returns And Helps Protect Against Market Panic
David Van Knapp - at Seeking Alpha - 1 hr 5 mins ago
KO: 42.52 (+0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), PG: 89.75 (+0.30), O: 46.90 (-0.20), CVX: 118.53 (+0.61), BRK.B: 144.81 (-0.24), BRK.A: 217,244.22 (-255.78)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)
Early Glance: Medical Devices companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.91 (+0.09), PFE: 30.25 (+0.05), MRK: 59.27 (+0.46), AZN: 74.29 (+1.08), LLY: 67.96 (-0.39), GSK: 45.83 (+0.67)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
La Lumiere Closes $20 Million Series B Financing
PR Newswire - Tue Nov 11, 7:02AM CST
Start-up skincare company La Lumiere, LLC, creator of the innovative illuMask®, the world's first wearable light therapy mask, announced today that it has secured a $20 million Series B financing. The investment included Johnson & Johnson Development Corporation (JJDC), the venture capital subsidiary of Johnson & Johnson, joining SWaN & Legend Venture Partners as institutional investors in the company. The Series B investment is a culmination of efforts over the last 12 months to drive commercialization in the U.S and continued growth.
JNJ: 108.91 (+0.09)
What Happened To The Dividend Growth Investor - The Most Telling Examples
Dale Roberts - at Seeking Alpha - Tue Nov 11, 6:32AM CST
KO: 42.52 (+0.13), CLX: 101.15 (-0.52), C: 53.81 (-0.08), XOM: 96.47 (+0.19), WMT: 78.99 (-0.45), VIG: 79.96 (-0.03), WFC: 53.67 (-0.16), BAC: 17.32 (-0.05), PEP: 96.84 (-0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), USB: 44.03 (+0.10), IBM: 163.65 (+0.16), GM: 31.32 (+0.20), MCD: 95.14 (+0.03), VYM: 68.97 (-0.05), AIG: 54.43 (+0.07), PG: 89.74 (+0.29), CVX: 118.53 (+0.61)
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part V
Robert Honeywill - Seeking Alpha - Tue Nov 11, 6:00AM CST
In Part IV of this series I provided tables (Cases 1 through 5) illustrating the potentially huge impact of higher or lower PE ratios for an investment in shares of Johnson & Johnson (NYSE: JNJ ). In "Bear" markets, the share prices...
SSH: 5.03 (+0.04), JNJ: 108.91 (+0.09)
Global Feminine Hygiene Products Market 2014-2018: Increasing Awareness, Intense Competition and High Brand Loyalty
M2 - Tue Nov 11, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9x9mz/global_feminine) has announced the addition of the "Global Feminine Hygiene Products Market 2014-2018" report to their offering. The Global Feminine Hygiene Products market to grow at a CAGR of 4.7% over the period 2013-2018 Hygiene is a science that aids in the maintenance of health and prevents the spread of diseases. Feminine hygiene products are personal care products that are used by women at the time of menstruation or vaginal discharge or bodily functions related to vulva. These products include sanitary napkins/pads, tampons, panty liners, menstrual cups, douches, intimate wash and sprays, and feminine wipes. One key trend upcoming in this market is high brand loyalty among consumers. Consumers loyal to their specific brands often refrain from trying out new ones. Hence, established vendors can maintain their consumer list and market share. According to the report, one of the major drivers of the market is the rise in awareness of the importance of hygiene among girls and women worldwide. Various campaigns and seminars about the safety measures to be taken while maintaining hygiene, and the usage, and disposal of hygiene products are conducted in schools and colleges worldwide. These have created demand for safe feminine hygiene products. Further, the report states that one major challenge in the market is the intense competition among vendors in the market. Many multinationals have dominant shares in the market, and this poses a threat to small-sized vendors. In addition, the emergence of many private-labels is intensifying competition. Key Vendors - Johnson & Johnson - Kimberly-Clark - Procter & Gamble - SCA Other Prominent Vendors - First Quality Enterprises - Fujian Hengan Group - Kao - Lil-Lets Group - Millie & More - My Bella Flor - Natracare - PayChest - Playtex Products - Seventh Generation - Uni-Charm For more information visit http://www.researchandmarkets.com/research/f9...l_feminine
JNJ: 108.91 (+0.09), PG: 89.74 (+0.29)
Cramer's Mad Money - Disney Is A Sleep At Night Stock (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:09AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 10. Disney (NYSE: DIS ) Is A Sleep At Night Stock. Other stocks mentioned: Baidu (NASDAQ: BIDU ), Vipshop (NYSE: VIPS ), Alibaba (NYSE: BABA ),...
WFM: 47.15 (-0.90), VIPS: 24.32 (-0.19), CLX: 101.15 (-0.52), XOM: 96.47 (+0.19), DIS: 89.70 (-0.08), BBY: 34.69 (-0.02), TM: 119.34 (+1.37), CELG: 107.64 (-0.37), WWAV: 36.28 (+0.28), JNJ: 108.91 (+0.09), BIDU: 247.61 (+0.03), GILD: 108.50 (+1.48), MRK: 59.27 (+0.46), EOG: 98.72 (+0.22), MCD: 95.14 (+0.03), CVX: 118.53 (+0.61), AAPL: 109.14 (+0.31), BABA: 114.90 (-4.25)
CORRECTING and REPLACING Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About Afib(SM)
Business Wire - Mon Nov 10, 6:40PM CST
Fourth paragraph, first sentence of release should read: Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first contact force therapy available in the U.S. (Instead of Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first and only contact force...).
JNJ: 108.91 (+0.09)
Final Glance: Pharmaceuticals companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.25 (+0.05), BMY: 58.71 (-0.10)
Final Glance: Medical Devices companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)
JNJ Johnson & Johnson Recent Headline News
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 35 mins ago
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)
Midday Glance: Pharmaceuticals companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)
Midday Glance: Medical Devices companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
Reinvesting Dividends Turbo-Charges Total Returns And Helps Protect Against Market Panic
David Van Knapp - at Seeking Alpha - 1 hr 5 mins ago
KO: 42.52 (+0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), PG: 89.75 (+0.30), O: 46.90 (-0.20), CVX: 118.53 (+0.61), BRK.B: 144.81 (-0.24), BRK.A: 217,244.22 (-255.78)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)
Early Glance: Medical Devices companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.91 (+0.09), PFE: 30.25 (+0.05), MRK: 59.27 (+0.46), AZN: 74.29 (+1.08), LLY: 67.96 (-0.39), GSK: 45.83 (+0.67)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)
La Lumiere Closes $20 Million Series B Financing
PR Newswire - Tue Nov 11, 7:02AM CST
Start-up skincare company La Lumiere, LLC, creator of the innovative illuMask®, the world's first wearable light therapy mask, announced today that it has secured a $20 million Series B financing. The investment included Johnson & Johnson Development Corporation (JJDC), the venture capital subsidiary of Johnson & Johnson, joining SWaN & Legend Venture Partners as institutional investors in the company. The Series B investment is a culmination of efforts over the last 12 months to drive commercialization in the U.S and continued growth.
JNJ: 108.91 (+0.09)
What Happened To The Dividend Growth Investor - The Most Telling Examples
Dale Roberts - at Seeking Alpha - Tue Nov 11, 6:32AM CST
KO: 42.52 (+0.13), CLX: 101.15 (-0.52), C: 53.81 (-0.08), XOM: 96.47 (+0.19), WMT: 78.99 (-0.45), VIG: 79.96 (-0.03), WFC: 53.67 (-0.16), BAC: 17.32 (-0.05), PEP: 96.84 (-0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), USB: 44.03 (+0.10), IBM: 163.65 (+0.16), GM: 31.32 (+0.20), MCD: 95.14 (+0.03), VYM: 68.97 (-0.05), AIG: 54.43 (+0.07), PG: 89.74 (+0.29), CVX: 118.53 (+0.61)
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part V
Robert Honeywill - Seeking Alpha - Tue Nov 11, 6:00AM CST
In Part IV of this series I provided tables (Cases 1 through 5) illustrating the potentially huge impact of higher or lower PE ratios for an investment in shares of Johnson & Johnson (NYSE: JNJ ). In "Bear" markets, the share prices...
SSH: 5.03 (+0.04), JNJ: 108.91 (+0.09)
Global Feminine Hygiene Products Market 2014-2018: Increasing Awareness, Intense Competition and High Brand Loyalty
M2 - Tue Nov 11, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9x9mz/global_feminine) has announced the addition of the "Global Feminine Hygiene Products Market 2014-2018" report to their offering. The Global Feminine Hygiene Products market to grow at a CAGR of 4.7% over the period 2013-2018 Hygiene is a science that aids in the maintenance of health and prevents the spread of diseases. Feminine hygiene products are personal care products that are used by women at the time of menstruation or vaginal discharge or bodily functions related to vulva. These products include sanitary napkins/pads, tampons, panty liners, menstrual cups, douches, intimate wash and sprays, and feminine wipes. One key trend upcoming in this market is high brand loyalty among consumers. Consumers loyal to their specific brands often refrain from trying out new ones. Hence, established vendors can maintain their consumer list and market share. According to the report, one of the major drivers of the market is the rise in awareness of the importance of hygiene among girls and women worldwide. Various campaigns and seminars about the safety measures to be taken while maintaining hygiene, and the usage, and disposal of hygiene products are conducted in schools and colleges worldwide. These have created demand for safe feminine hygiene products. Further, the report states that one major challenge in the market is the intense competition among vendors in the market. Many multinationals have dominant shares in the market, and this poses a threat to small-sized vendors. In addition, the emergence of many private-labels is intensifying competition. Key Vendors - Johnson & Johnson - Kimberly-Clark - Procter & Gamble - SCA Other Prominent Vendors - First Quality Enterprises - Fujian Hengan Group - Kao - Lil-Lets Group - Millie & More - My Bella Flor - Natracare - PayChest - Playtex Products - Seventh Generation - Uni-Charm For more information visit http://www.researchandmarkets.com/research/f9...l_feminine
JNJ: 108.91 (+0.09), PG: 89.74 (+0.29)
Cramer's Mad Money - Disney Is A Sleep At Night Stock (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:09AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 10. Disney (NYSE: DIS ) Is A Sleep At Night Stock. Other stocks mentioned: Baidu (NASDAQ: BIDU ), Vipshop (NYSE: VIPS ), Alibaba (NYSE: BABA ),...
WFM: 47.15 (-0.90), VIPS: 24.32 (-0.19), CLX: 101.15 (-0.52), XOM: 96.47 (+0.19), DIS: 89.70 (-0.08), BBY: 34.69 (-0.02), TM: 119.34 (+1.37), CELG: 107.64 (-0.37), WWAV: 36.28 (+0.28), JNJ: 108.91 (+0.09), BIDU: 247.61 (+0.03), GILD: 108.50 (+1.48), MRK: 59.27 (+0.46), EOG: 98.72 (+0.22), MCD: 95.14 (+0.03), CVX: 118.53 (+0.61), AAPL: 109.14 (+0.31), BABA: 114.90 (-4.25)
CORRECTING and REPLACING Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About Afib(SM)
Business Wire - Mon Nov 10, 6:40PM CST
Fourth paragraph, first sentence of release should read: Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first contact force therapy available in the U.S. (Instead of Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first and only contact force...).
JNJ: 108.91 (+0.09)
Final Glance: Pharmaceuticals companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.25 (+0.05), BMY: 58.71 (-0.10)
Final Glance: Medical Devices companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)
